Fibrotic processes are the underlying factors in a variety of difficult-to-treat diseases, resulting in progressive organ failure. Agomab aims to resolve these processes through a broad focused pipeline of small molecule and antibody drug candidates designed for their unique and novel modes of actions against well-validated and potentially disease modifying targets, ultimately leading to repair of tissue injury, resolution of fibrosis and restoration of organ function.